Antithetic roles of proteoglycans in cancer

Cellular and Molecular Life Sciences

Volumn 69, Issue 4, 2012, Pages 553-579

  Garusi, Elena ^a   Rossi, Silvia ^a   Perris, Roberto ^a,b  

^a UNIVERSITY OF PARMA   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Immunotherapeutics; Metastasis formation; Proteoglycans; Tumor growth; Tumor marker

Indexed keywords

ANTINEOPLASTIC AGENT; CHONDROITIN SULFATE PROTEOGLYCAN 4; GLYCOSAMINOGLYCAN; MIMECAN; MONOCLONAL ANTIBODY MK2 23; PERLECAN; PROTEOCHONDROITIN SULFATE; PROTEOGLYCAN; UNCLASSIFIED DRUG; VERSICAN;

CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PROGNOSIS; CANCER STEM CELL; CARCINOGENESIS; CELL INTERACTION; CELL INVASION; DRUG TARGETING; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; MELANOMA; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; HUMANS; IMMUNOTHERAPY; NEOPLASMS; PROTEOGLYCANS; TUMOR MARKERS, BIOLOGICAL;

EID: 84857050160     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-011-0816-1     Document Type: Review

References (266)

1. Iozzo RV (2005) Basement membrane proteoglycans: from cellar to ceiling. Nat Rev Mol Cell Biol 6:646-656 (Pubitemid 41081268)
2. Cattaruzza S, Perris R (2005) Proteoglycan control of cell movement during wound healing and cancer spreading. Matrix Biol 24:400-417 (Pubitemid 41765019)
3. Fico A, Maina F, Dono R (2011) Fine-tuning of cell signalling by glypicans. Cell Mol Life Sci 68:923-929
4. Stallcup WB, Huang FJ (2008) A role for the NG2 proteoglycan in glioma progression. Cell Adh Migr 2:192-201
5. Campoli M, Ferrone S, Wang X (2010) Functional and clinical relevance of chondroitin sulfate proteoglycan 4. Adv Cancer Res 109:73-121
6. Couchman JR (2010) Transmembrane signaling proteoglycans. Annu Rev Cell Dev Biol 26:89-114
7. Theocharis AD, Skandalis SS, Tzanakakis GN, Karamanos NK (2010) Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting. FEBS J 277:3904-3923
8. Iozzo RV, Sanderson RD (2011) Proteoglycans in cancer biology, tumor microenvironment and angiogenesis. J Cell Mol Med 15:1013-1031
9. Kalgsbrun M (1976) The decreased synthesis of chondroitin sulfate-containing extracellular proteoglycans by SV40 transformed Balb/c 3T3 cells. Biochim Biophys Acta 451:170-183
10. Hayman EG, Oldberg A, Martin GR, Ruoslahti E (1982) Codistribution of heparan sulfate proteoglycan, laminin, and fibronectin in the extracellular matrix of normal rat kidney cells and their coordinate absence in transformed cells. J Cell Biol 94:28-35 (Pubitemid 12033660)
11. Bumol TF, Reisfeld RA (1982) Unique glycoprotein-proteoglycan complex defined by monoclonal antibody on human melanoma cells. Proc Natl Acad Sci USA 79:1245-1249 (Pubitemid 12105584)
12. Wilson BS, Ruberto G, Ferrone S (1983) Immunochemical characterization of a human high molecular weight-melanomaassociated antigen identified with monoclonal antibodies. Cancer lmmunol Immunother 14:196-201 (Pubitemid 13117135)
13. Hellström IH, Garrigues HJ, Cabasco L, Mosely GH, Brown JP, Hellström KE (1983) Studies of a high molecular weight human melanoma-associated antigen. J lmmunol 130:1467-1472
14. Ross AH, Cossu G, Herlyn M, Bell JR, Steplewski Z, Koprowski H (1983) Isolation and chemical characterization of a melanoma-associated proteoglycan antigen. Arch Biochem Biophys 225:370-383
15. Pluschke G, Vanek M, Evans A, Dittmar T, Schmid P, Itin P, Filardo EJ, Reisfeld RA (1996) Molecular cloning of a human melanoma-associated chondroitin sulfate proteoglycan. Proc Natl Acad Sci USA 93:9710-9715 (Pubitemid 26296674)
16. Brézillon S, Venteo L, Ramont L, D'Onofrio MF, Perreau C, Pluot M, Maquart FX, Wegrowski Y (2007) Expression of lumican, a small leucine-rich proteoglycan with antitumour activity, in human malignant melanoma. Clin Exp Dermatol 32:405-416 (Pubitemid 46828334)
17. Nishino R, Honda M, Yamashita T, Takatori H, Minato H, Zen Y, Sasaki M, Takamura H, Horimoto K, Ohta T, Nakanuma Y, Kaneko S (2008) Identification of novel candidate tumour marker genes for intrahepatic cholangiocarcinoma. J Hepatol 49:207-216
18. Assheton DC, Guerin EP, Sheridan CM, Bishop PN, Hiscott PS (2007) Neoplastic transformation of ciliary body epithelium is associated with loss of opticin expression. Br J Ophthalmol 91:230-232 (Pubitemid 46202876)
19. Touab M, Villena J, Barranco C, Arumí-Uría M, Bassols A (2002) Versican is differentially expressed in human melanoma and may play a role in tumor development. Am J Pathol 160:549-557 (Pubitemid 34160332)
20. Domenzain C, Docampo MJ, Serra M, Miquel L, Bassols A (2003) Differential expression of versican isoforms is a component of the human melanoma cell differentiation process. Biochim Biophys Acta 1642:107-114 (Pubitemid 37338284)
21. Galamb O, Sipos F, Spisák S, Galamb B, Krenács T, Valcz G, Tulassay Z, Molnár B (2009) Potential biomarkers of colorectal adenoma-dysplasia-carcinoma progression: mRNA expression profiling and in situ protein detection on TMAs reveal 15 sequentially upregulated and 2 downregulated genes. Cell Oncol 31:19-29
22. Nikitovic D, Berdiaki A, Zafiropoulos A, Katonis P, Tsatsakis A, Karamanos NK, Tzanakakis GN (2008) Lumican expression is positively correlated with the differentiation and negatively with the growth of human osteosarcoma cells. FEBS J 275:350-361
23. Dobra K, Andäng M, Syrokou A, Karamanos NK, Hjerpe A (2000) Differentiation of mesothelioma cells is influenced by the expression of proteoglycans. Exp Cell Res 258:12-22 (Pubitemid 30461103)
24. Ghiselli G, Iozzo RV (2000) Overexpression of bamacan/SMC3 causes transformation. J Biol Chem 275:20235-20238 (Pubitemid 30457592)
25. Scherpereel A, Gentina T, Grigoriu B, Sénéchal S, Janin A, Tsicopoulos A, Plénat F, Béchard D, Tonnel AB, Lassalle P (2003) Overexpression of endocan induces tumor formation. Cancer Res 63:6084-6089 (Pubitemid 37187514)
26. Calzolari F, Appolloni I, Tutucci E, Caviglia S, Terrile M, Corte G, Malatesta P (2008) Tumor progression and oncogene addiction in a PDGF-B-induced model of gliomagenesis. Neoplasia 10:1373-1382
27. Grako KA, Ochiya T, Barritt D, Nishiyama A, Stallcup WB (1999) PDGF (alpha)-receptor is unresponsive to PDGF-AA in aortic smooth muscle cells from the NG2 knockout mouse. J Cell Sci 112:905-915 (Pubitemid 29179323)
28. Goretzki L, Burg MA, Grako KA, Stallcup WB (1999) Highaffinity binding of basic fibroblast growth factor and plateletderived growth factor-AA to the core protein of the NG2 proteoglycan. J Biol Chem 274:16831-16837
29. Terrile M, Appolloni I, Calzolari F, Perris R, Tutucci E, Malatesta P (2010) PDGF-B-driven gliomagenesis can occur in the absence of the proteoglycan NG2. BMC Cancer 10:550
30. Inki P, Stenbäck F, Talve L, Jalkanen M (1991) Immunohistochemical localization of syndecan in mouse skin tumors induced by UV irradiation. Loss of expression associated with malignant transformation. Am J Pathol 139:1333-1340
31. Inki P, Larjava H, Haapasalmi K, Miettinen HM, Grenman R, Jalkanen M (1994) Expression of syndecan-1 is induced by differentiation and suppressed by malignant transformation of human keratinocytes. Eur J Cell Biol 63:43-51 (Pubitemid 2039154)
32. Bayer-Garner IB, Dilday B, Sanderson RD, Smoller BR (2000) Syndecan-1 expression is decreased with increasing aggressiveness of basal cell carcinoma. Am J Dermatopathol 22:119-122 (Pubitemid 30185832)
33. Bayer-Garner IB, Smoller BR (2001) The expression of syndecan-1 is preferentially reduced compared with that of E-cadherin in acantholytic squamous cell carcinoma. J Cutan Pathol 28:83-89 (Pubitemid 32056615)
34. Stepp MA, Pal-Ghosh S, Tadvalkar G, Rajjoub L, Jurjus RA, Gerdes M, Ryscavage A, Cataisson C, Shukla A, Yuspa SH (2010) Loss of syndecan-1 is associated with malignant conversion in skin carcinogenesis. Mol Carcinog 49:363-373
35. Kato M, Saunders S, Nguyen H, Bernfield M (1995) Loss of cell surface syndecan-1 causes epithelia to transform into anchorageindependent mesenchyme-like cells. Mol Biol Cell 6:559-576
36. Matsumoto A, Ono M, Fujimoto Y, Gallo RL, Bernfield M, Kohgo Y (1997) Reduced expression of syndecan-1 in human hepatocellular carcinoma with high metastatic potential. Int J Cancer 74:482-491 (Pubitemid 27486504)
37. Soukka T, Pohjola J, Inki P, Happonen RP (2000) Reduction of syndecan-1 expression is associated with dysplastic oral epithelium. J Oral Pathol Med 29:308-313 (Pubitemid 30459302)
38. Harada K, Masuda S, Hirano M, Nakanuma Y (2003) Reduced expression of syndecan-1 correlates with histologic dedifferentiation, lymph node metastasis, and poor prognosis in intrahepatic cholangiocarcinoma. Hum Pathol 34:857-863 (Pubitemid 37169614)
39. Watari J, Saitoh Y, Fujiya M, Shibata N, Tanabe H, Inaba Y, Okamoto K, Maemoto A, Ohta T, Yasuda A, Ayabe T, Ashida T, Yokota K, Obara T, Kohgo Y (2004) Reduction of syndecan-1 expression in differentiated type early gastric cancer and background mucosa with gastric cellular phenotype. J Gastroenterol 39:104-112 (Pubitemid 38325185)
40. Mennerich D, Vogel A, Klaman I, Dahl E, Lichtner RB, Rosenthal A, Pohlenz HD, Thierauch KH, Sommer A (2004) Shift of syndecan-1 expression from epithelial to stromal cells during progression of solid tumours. Eur J Cancer 40:1373-1382 (Pubitemid 38737024)
41. Hasengaow A, Kodama J, Kusumoto T, Shinyo Y, Seki N, Hiramatsu Y (2005) Prognostic significance of syndecan-1 expression in human endometrial cancer. Ann Oncol 16:1109-1115 (Pubitemid 41418313)
42. Shinyo Y, Kodama J, Hasengaowa, Kusumoto T, Hiramatsu Y (2005) Loss of cell-surface heparan sulfate expression in both cervical intraepithelial neoplasm and invasive cervical cancer. Gynecol Oncol 96:776-783 (Pubitemid 40255501)
43. Kambham N, Kong C, Longacre TA, Natkunam Y (2005) Utility of syndecan-1 (CD138) expression in the diagnosis of undifferentiated malignant neoplasms: a tissue microarray study of 1, 754 cases. Appl Immunohistochem Mol Morphol 13:304-310 (Pubitemid 41697391)
44. Hashimoto Y, Skacel M, Adams JC (2008) Association of loss of epithelial syndecan-1 with stage and local metastasis of colorectal adenocarcinomas: an immunohistochemical study of clinically annotated tumors. BMC Cancer 8:185
45. Kusumoto T, Kodama J, Seki N, Nakamura K, Hongo A, Hiramatsu Y (2010) Clinical significance of syndecan-1 and versican expression in human epithelial ovarian cancer. Oncol Rep 23:917-925
46. Alexander CM, Reichsman F, Hinkes MT, Lincecum J, Becker KA, Cumberledge S, Bernfield M (2000) Syndecan-1 is required for Wnt-1-induced mammary tumorigenesis in mice. Nat Genet 25:329-332 (Pubitemid 30437323)
47. McDermott SP, Ranheim EA, Leatherberry VS, Khwaja SS, Klos KS, Alexander CM (2007) Juvenile syndecan-1 null mice are protected from carcinogen-induced tumor development. Oncogene 26:1407-1416 (Pubitemid 46340817)
48. Lin H, Huber R, Schlessinger D, Morin PJ (1999) Frequent silencing of the GPC3 gene in ovarian cancer cell lines. Cancer Res 59:807-810 (Pubitemid 29086731)
49. Murthy SS, Shen T, De Rienzo A, Lee WC, Ferriola PC, Jhanwar SC, Mossman BT, Filmus J, Testa JR (2000) Expression of GPC3, an X-linked recessive overgrowth gene, is silenced in malignant mesothelioma. Oncogene 19:410-416 (Pubitemid 30077342)
50. Xiang YY, Ladeda V, Filmus J (2001) Glypican-3 expression is silenced in human breast cancer. Oncogene 20:7408-7412 (Pubitemid 33078211)
51. Zhu ZW, Friess H, Wang L, Abou-Shady M, Zimmermann A, Lander AD, Korc M, Kleeff J, Büchler MW (2001) Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut 48:558-564 (Pubitemid 32234802)
52. Kim H, Xu GL, Borczuk AC, Busch S, Filmus J, Capurro M, Brody JS, Lange J, D'Armiento JM, Rothman PB, Powell CA (2003) The heparan sulfate proteoglycan GPC3 is a potential lung tumor suppressor. Am J Respir Cell Mol Biol 29:694-701 (Pubitemid 38054366)
53. Stadlmann S, Gueth U, Baumhoer D, Moch H, Terracciano L, Singer G (2007) Glypican-3 expression in primary and recurrent ovarian carcinomas. Int J Gynecol Pathol 26:341-344 (Pubitemid 46986073)
54. Aviel-Ronen S, Lau SK, Pintilie M, Lau D, Liu N, Tsao MS, Jothy S (2008) Glypican-3 is overexpressed in lung squamous cell carcinoma, but not in adenocarcinoma. Mod Pathol 21:817-825 (Pubitemid 351896655)
55. Li Y, Sheu CC, Ye Y, de Andrade M, Wang L, Chang SC, Aubry MC, Aakre JA, Allen MS, Chen F, Cunningham JM, Deschamps C, Jiang R, Lin J, Marks RS, Pankratz VS, Su L, Li Y, Sun Z, Tang H, Vasmatzis G, Harris CC, Spitz MR, Jen J, Wang R, Zhang ZF, Christiani DC, Wu X, Yang P (2010) Genetic variants and risk of lung cancer in never smokers: a genome-wide association study. Lancet Oncol 11:321-330
56. de Leeuw RJ, Davies JJ, Rosenwald A, Bebb G, Gascoyne RD, Dyer MJ, Staudt LM, Martinez-Climent JA, Lam WL (2004) Comprehensive whole genome array CGH profiling of mantle cell lymphoma model genomes. Hum Mol Genet 13:1827-1837 (Pubitemid 39214331)
57. Schraders M, Pfundt R, Straatman HM, Janssen IM, van Kessel AG, Schoenmakers EF, van Krieken JH, Groenen PJ (2005) Novel chromosomal imbalances in mantle cell lymphoma detected by genome-wide array-based comparative genomic hybridization. Blood 105:1686-1693 (Pubitemid 40223691)
58. Yu W, Inoue J, Imoto I, Matsuo Y, Karpas A, Inazawa J (2003) GPC5 is a possible target for the 13q31-q32 amplification detected in lymphoma cell lines. J Hum Genet 48:331-335 (Pubitemid 36834363)
59. Williamson D, Selfe J, Gordon T, Lu YJ, Pritchard-Jones K, Murai K, Jones P, Workman P, Shipley J (2007) Role for amplification and expression of glypican-5 in rhabdomyosarcoma. Cancer Res 67:57-65 (Pubitemid 46142759)
60. Yoshioka N, Inoue H, Nakanishi K, Oka K, Yutsudo M, Yamashita A, Hakura A, Nojima H (2000) Isolation of transformation suppressor genes by cDNA subtraction: lumican suppresses transformation induced by v-src and v-K-ras. J Virol 74:1008-1013 (Pubitemid 30036239)
61. Vuillermoz B, Khoruzhenko A, D'Onofrio MF, Ramont L, Venteo L, Perreau C, Antonicelli F, Maquart FX, Wegrowski Y (2004) The small leucine-rich proteoglycan lumican inhibits melanoma progression. Exp Cell Res 296:294-306 (Pubitemid 38624650)
62. Wang Y, Ma Y, Lü B, Xu E, Huang Q, Lai M (2007) Differential expression of mimecan and thioredoxin domaincontaining protein 5 in colorectal adenoma and cancer: a proteomic study. Exp Biol Med (Maywood) 232:1152-1159 (Pubitemid 47503056)
63. Yamaguchi Y, Mann DM, Ruoslahti E (1990) Negative regulation of transforming growth factor-beta by the proteoglycan decorin. Nature 346:281-284
64. Santra M, Mann DM, Mercer EW, Skorski T, Calabretta B, Iozzo RV (1997) Ectopic expression of decorin protein core causes a generalized growth suppression in neoplastic cells of various histogenetic origin and requires endogenous p21, an inhibitor of cyclin-dependent kinases. J Clin Invest 100:149-157 (Pubitemid 27311253)
65. Grant DS, Yenisey C, Rose RW, Tootell M, Santra M, Iozzo RV (2002) Decorin suppresses tumor cell-mediated angiogenesis. Oncogene 21:4765-4777 (Pubitemid 34879452)
66. Reed CC, Waterhouse A, Kirby S, Kay P, Owens RT, McQuillan DJ, Iozzo RV (2005) Decorin prevents metastatic spreading of breast cancer. Oncogene 24:1104-1110 (Pubitemid 40313888)
67. Shintani K, Matsumine A, Kusuzaki K, Morikawa J, Matsubara T, Wakabayashi T, Araki K, Satonaka H, Wakabayashi H, Iino T, Uchida A (2008) Decorin suppresses lung metastases of murine osteosarcoma. Oncol Rep 19:1533-1539
68. Goldoni S, Seidler DG, Heath J, Fassan M, Baffa R, Thakur ML, Owens RT, McQuillan DJ, Iozzo RV (2008) An antimetastatic role for decorin in breast cancer. Am J Pathol 173:844-855
69. Araki K, Wakabayashi H, Shintani K, Morikawa J, Matsumine A, Kusuzaki K, Sudo A, Uchida A (2009) Decorin suppresses bone metastasis in a breast cancer cell line. Oncology 77:92-99
70. Bi X, Tong C, Dockendorff A, Bancroft L, Gallagher L, Guzman G, Iozzo RV, Augenlicht LH, Yang W (2008) Genetic deficiency of decorin causes intestinal tumor formation through disruption of intestinal cell maturation. Carcinogenesis 29:1435-1440
71. Kolettas E, Rosenberger RF (1998) Suppression of decorin expression and partial induction of anchorage-independent growth by the v-src oncogene in human fibroblasts. Eur J Biochem 254:266-274 (Pubitemid 28289379)
72. Matsumine A, Shintani K, Kusuzaki K, Matsubara T, Satonaka H, Wakabayashi T, Iino T, Uchida A (2007) Expression of decorin, a small leucine-rich proteoglycan, as a prognostic factor in soft tissue tumors. J Surg Oncol 96:411-418 (Pubitemid 47519447)
73. McDoniels-Silvers AL, Nimri CF, Stoner GD, Lubet RA, You M (2002) Differential gene expression in human lung adenocarcinomas and squamous cell carcinomas. Clin Cancer Res 8:1127-1138 (Pubitemid 35177366)
74. Troup S, Njue C, Kliewer EV, Parisien M, Roskelley C, Chakravarti S, Roughley PJ, Murphy LC, Watson PH (2003) Reduced expression of the small leucine-rich proteoglycans, lumican, and decorin is associated with poor outcome in nodenegative invasive breast cancer. Clin Cancer Res 9:207-214 (Pubitemid 36109735)
75. Adatia R, Albini A, Carlone S, Giunciuglio D, Benelli R, Santi L, Noonan DM (1997) Suppression of invasive behavior of melanoma cells by stable expression of anti-sense perlecan cDNA. Ann Oncol 8:1257-1261 (Pubitemid 28164082)
76. Savorè C, Zhang C, Muir C, Liu R, Wyrwa J, Shu J, Zhau HE, Chung LW, Carson DD, Farach-Carson MC (2005) Perlecan knockdown in metastatic prostate cancer cells reduces heparinbinding growth factor responses in vitro and tumor growth in vivo. Clin Exp Metastasis 22:377-390 (Pubitemid 41609297)
77. Mathiak M, Yenisey C, Grant DS, Sharma B, Iozzo RV (1997) A role for perlecan in the suppression of growth and invasion in fibrosarcoma cells. Cancer Res 57:2130-2136 (Pubitemid 27247026)
78. Sharma B, Handler M, Eichstetter I, Whitelock J, Nugent MA, Iozzo RV (1998) Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo. J Clin Invest 102:1599-1608 (Pubitemid 28492228)
79. Zhou Z, Wang J, Cao R, Morita H, Soininen R, Chan KM, Liu B, Cao Y, Tryggvason K (2004) Impaired angiogenesis, delayed wound healing and retarded tumor growth in perlecan heparan sulfate-deficient mice. Cancer Res 64:4699-4702 (Pubitemid 38924508)
80. Bix G, Fu J, Gonzalez EM, Macro L, Barker A, Campbell S, Zutter MM, Santoro SA, Kim JK, Höök M, Reed CC, Iozzo RV (2004) Endorepellin causes endothelial cell disassembly of actin cytoskeleton and focal adhesions through alpha2beta1 integrin. J Cell Biol 166:97-109 (Pubitemid 38931920)
81. Bix G, Iozzo RA, Woodall B, Burrows M, McQuillan A, Campbell S, Fields GB, Iozzo RV (2007) Endorepellin, the C-terminal angiostatic module of perlecan, enhances collagenplatelet responses via the alpha2beta1-integrin receptor. Blood 109:3745-3748 (Pubitemid 46641724)
82. Woodall BP, Nyström A, Iozzo RA, Eble JA, Niland S, Krieg T, Eckes B, Pozzi A, Iozzo RV (2008) Integrin alpha2beta1 is the required receptor for endorepellin angiostatic activity. J Biol Chem 283:2335-2343
83. Aviezer D, Iozzo RV, Noonan DM, Yayon A (1997) Suppression of autocrine and paracrine functions of basic fibroblast growth factor by stable expression of perlecan antisense cDNA. Mol Cell Biol 17:1938-1946 (Pubitemid 27133278)
84. Mongiat M, Taylor K, Otto J, Aho S, Uitto J, Whitelock JM, Iozzo RV (2000) The protein core of the proteoglycan perlecan binds specifically to fibroblast growth factor-7. J Biol Chem 275:7095-7100 (Pubitemid 30146257)
85. Mongiat M, Otto J, Oldershaw R, Ferrer F, Sato JD, Iozzo RV (2001) Fibroblast growth factor-binding protein is a novel partner for perlecan protein core. J Biol Chem 276:10263-10271
86. Ghiselli G, Eichstetter I, Iozzo RV (2001) A role for the perlecan protein core in the activation of the keratinocyte growth factor receptor. Biochem J 359:153-163 (Pubitemid 32939217)
87. Knox S, Merry C, Stringer S, Melrose J, Whitelock J (2002) Not all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors. J Biol Chem 277:14657-14665 (Pubitemid 34952534)
88. Chuang CY, Lord MS, Melrose J, Rees MD, Knox SM, Freeman C, Iozzo RV, Whitelock JM (2010) Heparan sulfate-dependent signaling of fibroblast growth factor 18 by chondrocyte-derived perlecan. Biochemistry 49:5524-5532
89. Mongiat M, Sweeney SM, San Antonio JD, Fu J, Iozzo RV (2003) Endorepellin, a novel inhibitor of angiogenesis derived from the C terminus of perlecan. J Biol Chem 278:4238-4249 (Pubitemid 36801161)
90. Bix G, Castello R, Burrows M, Zoeller JJ, Weech M, Iozzo RA, Cardi C, Thakur ML, Barker CA, Camphausen K, Iozzo RV (2006) Endorepellin in vivo: targeting the tumor vasculature and retarding cancer growth and metabolism. J Natl Cancer Inst 98:1634-1646 (Pubitemid 44811646)
91. Hernández D, Miquel-Serra L, Docampo MJ, Marco-Ramell A, Bassols A (2011) Role of versican V0/V1 and CD44 in the regulation of human melanoma cell behavior. Int J Mol Med 27:269-275
92. Serra M, Miquel L, Domenzain C, Docampo MJ, Fabra A, Wight TN, Bassols A (2005) V3 versican isoform expression alters the phenotype of melanoma cells and their tumorigenic potential. Int J Cancer 114:879-886
93. Miquel-Serra L, Serra M, Hernández D, Domenzain C, Docampo MJ, Rabanal RM, de Torres I, Wight TN, Fabra A, Bassols A (2006) V3 versican isoform expression has a dual role in human melanoma tumor growth and metastasis. Lab Invest 86:889-901 (Pubitemid 44268164)
94. Hernández D, Miquel-Serra L, Docampo MJ, Marco-Ramell A, Cabrera J, Fabra A, Bassols A (2011) V3 versican isoform alters the behavior of human melanoma cells by interfering with CD44/ErbB-dependent signaling. J Biol Chem 286:1475-1485
95. Cattaruzza S, Schiappacassi M, Ljungberg-Rose A, Spessotto P, Perissinotto D, Mörgelin M, Mucignat MT, Colombatti A, Perris R (2002) Distribution of PG-M/versican variants in human tissues and de novo expression of isoform V3 upon endothelial cell activation, migration, and neoangiogenesis in vitro. J Biol Chem 277:47626-47635 (Pubitemid 36159284)
96. LaPierre DP, Lee DY, Li SZ, Xie YZ, Zhong L, Sheng W, Deng Z, Yang BB (2007) The ability of versican to simultaneously cause apoptotic resistance and sensitivity. Cancer Res 67:4742-4750 (Pubitemid 46910181)
97. Zheng PS, Wen J, Ang LC, Sheng W, Viloria-Petit A, Wang Y, Wu Y, Kerbel RS, Yang BB (2004) Versican/PG-M G3 domain promotes tumor growth and angiogenesis. FASEB J 18:754-756
98. Yee AJ, Akens M, Yang BL, Finkelstein J, Zheng PS, Deng Z, Yang B (2007) The effect of versican G3 domain on local breast cancer invasiveness and bony metastasis. Breast Cancer Res 9:R47
99. Du WW, Yang BB, Shatseva TA, Yang BL, Deng Z, Shan SW, Lee DY, Seth A, Yee AJ (2010) Versican G3 promotes mouse mammary tumor cell growth, migration, and metastasis by influencing EGF receptor signaling. PLoS One 5:e13828
100. Wu Y, Chen L, Cao L, Sheng W, Yang BB (2004) Overexpression of the C-terminal PG-M/versican domain impairs growth of tumor cells by intervening in the interaction between epidermal growth factor receptor and beta1-integrin. J Cell Sci 117:2227-2237 (Pubitemid 38807491)
101. Neudenberger J, Hotfilder M, Rosemann A, Langebrake C, Reinhardt D, Pieters R, Schrauder A, Schrappe M, Röttgers S, Harbott J, Vormoor J (2006) Lack of expression of the chondroitin sulphate proteoglycan neuron-glial antigen 2 on candidate stem cell populations in paediatric acute myeloid leukaemia/abn(11q23) and acute lymphoblastic leukaemia/t(4;11). Br J Haematol 133:337-344
102. Wang X, Wang Y, Yu L, Sakakura K, Visus C, Schwab JH, Ferrone CR, Favoino E, Koya Y, Campoli MR, McCarthy JB, DeLeo AB, Ferrone S (2010) CSPG4 in cancer: multiple roles. Curr Mol Med 10:419-429
103. Carbone A, Gloghini A, Gattei V, Degan M, Improta S, Aldinucci D, Canzonieri V, Perin T, Volpe R, Gaidano G, Zagonel V, Pinto A (1997) Reed-Sternberg cells of classical Hodgkin's disease react with the plasma cell-specific monoclonal antibody B-B4 and express human syndecan-1. Blood 89:3787-3794 (Pubitemid 27227103)
104. Costes V, Magen V, Legouffe E, Durand L, Baldet P, Rossi JF, Klein B, Brochier J (1999) The Mi15 monoclonal antibody (anti-syndecan-1) is a reliable marker for quantifying plasma cells in paraffin-embedded bone marrow biopsy specimens. Hum Pathol 30:1405-1411 (Pubitemid 30032914)
105. O'Connell FP, Pinkus JL, Pinkus GS (2004) CD138 (syndecan-1), a plasma cell marker immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms. Am J Clin Pathol 121:254-263 (Pubitemid 38140131)
106. Oh YH, Park CK (2006) Prognostic evaluation of nodal diffuse large B cell lymphoma by immunohistochemical profiles with emphasis on CD138 expression as a poor prognostic factor. J Korean Med Sci 21:397-405
107. Smith FO, Rauch C, Williams DE, March CJ, Arthur D, Hilden J, Lampkin BC, Buckley JD, Buckley CV, Woods WG, Dinndorf PA, Sorensen P, Kersey J, Hammond D, Bernstein ID (1996) The human homologue of rat NG2, a chondroitin sulfate proteoglycan, is not expressed on the cell surface of normal hematopoietic cells but is expressed by acute myeloid leukemia blasts from poor-prognosis patients with abnormalities of chromosome band 11q23. Blood 87:1123-1133
108. Behm FG, Smith FO, Raimondi SC, Pui CH, Bernstein ID (1996) Human homologue of the rat chondroitin sulfate proteoglycan, NG2, detected by monoclonal antibody 7.1, identifies childhood acute lymphoblastic leukemias with t(4;11)(q21;q23) or t(11;19)(q23;p13) and MLL gene rearrangements. Blood 87:1134-1139
109. Hilden JM, Smith FO, Frestedt JL, McGlennen R, Howells WB, Sorensen PH, Arthur DC, Woods WG, Buckley J, Bernstein ID, Kersey JH (1997) MLL gene rearrangement, cytogenetic 11q23 abnormalities, and expression of the NG2 molecule in infant acute myeloid leukemia. Blood 89:3801-3805 (Pubitemid 27227105)
110. Mauvieux L, Delabesse E, Bourquelot P, Radford-Weiss I, Bennaceur A, Flandrin G, Valensi F, MacIntyre EA (1999) NG2 expression in MLL rearranged acute myeloid leukaemia is restricted to monoblastic cases. Br J Haematol 107:674-676
111. Wuchter C, Harbott J, Schoch C, Schnittger S, Borkhardt A, Karawajew L, Ratei R, Ruppert V, Haferlach T, Creutzig U, Dörken B, Ludwig WD (2000) Detection of acute leukemia cells with mixed lineage leukemia (MLL) gene rearrangements by flow cytometry using monoclonal antibody 7.1. Leukemia 14:1232-1238 (Pubitemid 30445030)
112. Schwartz S, Rieder H, Schläger B, Burmeister T, Fischer L, Thiel E (2003) Expression of the human homologue of rat NG2 in adult acute lymphoblastic leukemia: close association with MLL rearrangement and a CD10(-)/CD24(-)/ CD65s(?)/CD15(?) B-cell phenotype. Leukemia 17:1589-1595 (Pubitemid 36986961)
113. Bueno C, Montes R, Martín L, Prat I, Hernandez MC, Orfao A, Menendez P (2008) NG2 antigen is expressed in CD34? HPCs and plasmacytoid dendritic cell precursors: is NG2 expression in leukemia dependent on the target cell where leukemogenesis is triggered? Leukemia 22:1475-1478
114. Petrovici K, Graf M, Hecht K, Reif S, Pfister K, Schmetzer H (2010) Use of NG2 (7.1) in AML as a tumor marker and its association with a poor prognosis. Cancer Genomics Proteomics 7:173-180
115. Niemann CU, Kjeldsen L, Ralfkiaer E, Jensen MK, Borregaard N (2007) Serglycin proteoglycan in hematologic malignancies: a marker of acute myeloid leukemia. Leukemia 21:2406-2410 (Pubitemid 350148881)
116. Theocharis AD, Seidel C, Borset M, Dobra K, Baykov V, Labropoulou V, Kanakis I, Dalas E, Karamanos NK, Sundan A, Hjerpe A (2006) Serglycin constitutively secreted by myeloma plasma cells is a potent inhibitor of bone mineralization in vitro. J Biol Chem 281:35116-35128 (Pubitemid 46036551)
117. Nakatsura T, Yoshitake Y, Senju S, Monji M, Komori H, Motomura Y, Hosaka S, Beppu T, Ishiko T, Kamohara H, Ashihara H, Katagiri T, Furukawa Y, Fujiyama S, Ogawa M, Nakamura Y, Nishimura Y (2003) Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 306:16-25 (Pubitemid 36629398)
118. CapurroM,Wanless IR, ShermanM, DeboerG, ShiW,Miyoshi E, Filmus J (2003) Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 125:89-97 (Pubitemid 36799110)
119. Midorikawa Y, Ishikawa S, Iwanari H, Imamura T, Sakamoto H, Miyazono K, Kodama T, Makuuchi M, Aburatani H (2003) Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling. Int J Cancer 103:455-465 (Pubitemid 36020219)
120. Hippo Y, Watanabe K, Watanabe A, Midorikawa Y, Yamamoto S, Ihara S, Tokita S, Iwanari H, Ito Y, Nakano K, Nezu J, Tsunoda H, Yoshino T, Ohizumi I, Tsuchiya M, Ohnishi S, Makuuchi M, Hamakubo T, Kodama T, Aburatani H (2004) Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early stage hepatocellular carcinoma. Cancer Res 64:2418-2423 (Pubitemid 38523895)
121. Yamaguchi N,Watanabe A, Hishinuma M, Ohashi K, Midorikawa Y, Morishita Y, Niki T, Shibahara J, Mori M,Makuuchi M, Hippo Y, Kodama T, Iwanari H, Aburatani H, Fukayama M (2005) The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol 18:1591-1598 (Pubitemid 41670658)
122. Baumhoer D, Tornillo L, Stadlmann S, Roncalli M, Diamantis EK, Terracciano LM (2008) Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples. Am J Clin Pathol 129:899-906
123. Lage H, Kellner U, Tannapfel A, Dietel M (2001) Expression of a glypican-related 62-kDa antigen is decreased in hepatocellular carcinoma in correspondence to the grade of tumor differentiation. Virchows Arch 438:567-573 (Pubitemid 32662375)
124. Zheng CX, Zhao SX, Wang P, Yu HM, Wang CF, Han B, Su B, Xiang Y, Li XS, Li SX, Ma QY, Zhang RX, Wan HY, Song HD (2009) Different expression of mimecan as a marker for differential diagnosis between NSCLC and SCLC. Oncol Rep 22:1057-1061
125. Kageshita T, Kuriya N, Ono T, Horikoshi T, Takahashi M, Wong GY, Ferrone S (1993) Association of high molecular weight melanoma-associated antigen expression in primary acral lentiginous melanoma lesions with poor prognosis. Cancer Res 53:2830-2833 (Pubitemid 23180523)
126. Wiksten JP, Lundin J, Nordling S, Lundin M, Kokkola A, von Boguslawski K, Haglund C (2001) Epithelial and stromal syndecan-1 expression as predictor of outcome in patients with gastric cancer. Int J Cancer 95:1-6
127. Ricciardelli C, Mayne K, Sykes PJ, Raymond WA, McCaul K, Marshall VR, Horsfall DJ (1998) Elevated levels of versican but not decorin predict disease progression in early stage prostate cancer. Clin Cancer Res 4:963-967
128. Ricciardelli C, Brooks JH, Suwiwat S, Sakko AJ, Mayne K, Raymond WA, Seshadri R, LeBaron RG, Horsfall DJ (2002) Regulation of stromal versican expression by breast cancer cells and importance to relapse-free survival in patients with nodenegative primary breast cancer. Clin Cancer Res 8:1054-1060 (Pubitemid 35177355)
129. Shah L, Walter KL, Borczuk AC, Kawut SM, Sonett JR, Gorenstein LA, Ginsburg ME, Steinglass KM, Powell CA (2004) Expression of syndecan-1 and expression of epidermal growth factor receptor are associated with survival in patients with nonsmall cell lung carcinoma. Cancer 101:1632-1638 (Pubitemid 39318911)
130. Leivonen M, Lundin J, Nordling S, von Boguslawski K, Haglund C (2004) Prognostic value of syndecan-1 expression in breast cancer. Oncology 67:11-18 (Pubitemid 39370345)
131. Vergilis IJ, Szarek M, Ferrone S, Reynolds SR (2005) Presence and prognostic significance of melanoma-associated antigens CYT-MAA and HMW-MAA in serum of patients with melanoma. J Invest Dermatol 125:526-531
132. Seya T, Tanaka N, Shinji S, Yokoi K, Koizumi M, Teranishi N, Yamashita K, Tajiri T, Ishiwata T, Naito Z (2006) Lumican expression in advanced colorectal cancer with nodal metastasis correlates with poor prognosis. Oncol Rep 16:1225-1230
133. Loussouarn D, Campion L, Sagan C, Frenel JS, Dravet F, Classe JM, Pioud-Martigny R, Berton-Rigaud D, Bourbouloux E, Mosnier JF, Bataille FR, Campone M (2008) Prognostic impact of syndecan-1 expression in invasive ductal breast carcinomas. Br J Cancer 98:1993-1998 (Pubitemid 351821565)
134. Ohashi M, Kusumi T, Sato F, Kudo Y, Jin H, Akasaka H, Miyamoto K, Toyoki Y, Hakamada K, Kijima H (2009) Expression of syndecan-1 and E-cadherin is inversely correlated with poor patient's prognosis and recurrent status of extrahepatic bile duct carcinoma. Biomed Res 30:79-86
135. Kodama J, Hasengaowa KT, Kusumoto T, Seki N, Matsuo T, Ojima Y, Nakamura K, Hongo A, Hiramatsu Y (2007) Prognostic significance of stromal versican expression in human endometrial cancer. Ann Oncol 18:269-274 (Pubitemid 46323092)
136. Kodama J, Hasengaowa, Kusumoto T, Seki N, Matsuo T, Nakamura K, Hongo A, Hiramatsu Y (2007) Versican expression in human cervical cancer. Eur J Cancer 43:1460-1466 (Pubitemid 46874065)
137. Benassi MS, Pazzaglia L, Chiechi A, Alberghini M, Conti A, Cattaruzza S, Wassermann B, Picci P, Perris R (2009) NG2 expression predicts the metastasis formation in soft-tissue sarcoma patients. J Orthop Res 27:135-140
138. Li XJ, Ong CK, Cao Y, Xiang YQ, Shao JY, Ooi A, Peng LX, Lu WH, Zhang Z, Petillo D, Qin L, Bao YN, Zheng FJ, Chia CS, Iyer NG, Kang TB, Zeng YX, Soo KC, Trent JM, Teh BT, Qian CN (2011) Serglycin is a theranostic target in nasopharyngeal carcinoma that promotes metastasis. Cancer Res 71:3162-3172
139. Anttonen A, Leppä S, Ruotsalainen T, Alfthan H, Mattson K, Joensuu H (2003) Pretreatment serum syndecan-1 levels and outcome in small cell lung cancer patients treated with platinumbased chemotherapy. Lung Cancer 41:171-177 (Pubitemid 36842780)
140. Köninger J, Giese T, di Mola FF, Wente MN, Esposito I, Bachem MG, Giese NA, Büchler MW, Friess H (2004) Pancreatic tumor cells influence the composition of the extracellular matrix. Biochem Biophys Res Commun 322:943-949 (Pubitemid 39164444)
141. Götte M, Kersting C, Ruggiero M, Tio J, Tulusan AH, Kiesel L, Wülfing P (2006) Predictive value of syndecan-1 expression for the response to neoadjuvant chemotherapy of primary breast cancer. Anticancer Res 26:621-627 (Pubitemid 43206026)
142. Watanabe T, Komuro Y, Kiyomatsu T, Kanazawa T, Kazama Y, Tanaka J, Tanaka T, Yamamoto Y, Shirane M, Muto T, Nagawa H (2006) Prediction of sensitivity of rectal cancer cells in response to preoperative radiotherapy by DNA microarray analysis of gene expression profiles. Cancer Res 66:3370-3374
143. Orosco A, Fromigué O, Bazille C, Entz-Werle N, Levillain P, Marie PJ, Modrowski D (2007) Syndecan-2 affects the basal and chemotherapy-induced apoptosis in osteosarcoma. Cancer Res 67:3708-3715 (Pubitemid 46762156)
144. Voutilainen K, Anttila M, Sillanpää S, Tammi R, Tammi M, Saarikoski S, Kosma VM (2003) Versican in epithelial ovarian cancer: relation to hyaluronan, clinicopathologic factors and prognosis. Int J Cancer 107:359-364 (Pubitemid 37266454)
145. Pirinen R, Leinonen T, Böhm J, Johansson R, Ropponen K, Kumpulainen E, Kosma VM (2005) Versican in nonsmall cell lung cancer: relation to hyaluronan, clinicopathologic factors, and prognosis. Hum Pathol 36:44-50 (Pubitemid 40220332)
146. Pukkila M, Kosunen A, Ropponen K, Virtaniemi J, Kellokoski J, Kumpulainen E, Pirinen R, Nuutinen J, Johansson R, Kosma VM (2007) High stromal versican expression predicts unfavourable outcome in oral squamous cell carcinoma. J Clin Pathol 60:267-272 (Pubitemid 46447741)
147. Gambichler T, Kreuter A, Grothe S, Altmeyer P, Brockmeyer NH, Rotterdam S (2008) Versican overexpression in cutaneous malignant melanoma. Eur J Med Res 13:500-504
148. Kischel P, Waltregny D, Dumont B, Turtoi A, Greffe Y, Kirsch S, De Pauw E, Castronovo V (2010) Versican overexpression in human breast cancer lesions: known and new isoforms for stromal tumor targeting. Int J Cancer 126:640-650
149. Canavese G, Candelaresi G, Castellano I, Mano MP (2011) Expression of proteoglycan versican in in situ breast lesions: relations between stromal changes, histotype, and invasion. Pathol Res Pract 207:97-103
150. Suwiwat S, Ricciardelli C, Tammi R, Tammi M, Auvinen P, Kosma VM, LeBaron RG, Raymond WA, Tilley WD, Horsfall DJ (2004) Expression of extracellular matrix components versican, chondroitin sulfate, tenascin, and hyaluronan, and their association with disease outcome in node-negative breast cancer. Clin Cancer Res 10:2491-2498 (Pubitemid 38445711)
151. Pukkila MJ, Kosunen AS, Virtaniemi JA, Kumpulainen EJ, Johansson RT, Kellokoski JK, Nuutinen J, Kosma VM (2004) Versican expression in pharyngeal squamous cell carcinoma: an immunohistochemical study. J Clin Pathol 57:735-739 (Pubitemid 38901489)
152. Yamaguchi K, Mandai M, Oura T, Matsumura N, Hamanishi J, Baba T, Matsui S, Murphy SK, Konishi I (2010) Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes. Oncogene 29:1741-1752
153. Muramatsu K, Kusafuka K, Watanabe H, Mochizuki T, Nakajima T (2009) Ultrastructural immunolocalization of a cartilagespecific proteoglycan, aggrecan, in salivary pleomorphic adenomas. Med Mol Morphol 42:47-54
154. Takeuchi Y, Kodama Y, Matsumoto T (1994) Bone matrix decorin binds transforming growth factor-beta and enhances its bioactivity. J Biol Chem 269:32634-32638
155. Schönherr E, Broszat M, Brandan E, Bruckner P, Kresse H (1998) Decorin core protein fragment Leu155-Val260 interacts with TGF-beta but does not compete for decorin binding to type I collagen. Arch Biochem Biophys 355:241-248 (Pubitemid 28364375)
156. Ständer M, Naumann U, Dumitrescu L, Heneka M, Löschmann P, Gulbins E, Dichgans J, Weller M (1998) Decorin gene transfer-mediated suppression of TGF-beta synthesis abrogates experimental malignant glioma growth in vivo. Gene Ther 5:1187-1194 (Pubitemid 28448426)
157. Cabello-Verrugio C, Brandan E (2007) A novel modulatory mechanism of transforming growth factor-beta signaling through decorin and LRP-1. J Biol Chem 282:18842-18850 (Pubitemid 47100183)
158. Tsanou E, Ioachim E, Briasoulis E, Charchanti A, Damala K, Karavasilis V, Pavlidis N, Agnantis NJ (2004) Clinicopathological study of the expression of syndecan-1 in invasive breast carcinomas. Correlation with extracellular matrix components. J Exp Clin Cancer Res 23:641-650
159. Máthé M, Suba Z, Németh Z, Tátrai P, Füle T, Borgulya G, Barabás J, Kovalszky I (2006) Stromal syndecan-1 expression is an adverse prognostic factor in oral carcinomas. Oral Oncol 42:493-500 (Pubitemid 44304423)
160. Su G, Blaine SA, Qiao D, Friedl A (2007) Shedding of syndecan-1 by stromal fibroblasts stimulates human breast cancer cell proliferation via FGF2 activation. J Biol Chem 282:14906-14915 (Pubitemid 47093352)
161. Yang N, Mosher R, Seo S, Beebe D, Friedl A (2011) Syndecan-1 in breast cancer stroma fibroblasts regulates extracellular matrix fiber organization and carcinoma cell motility. Am J Pathol 178:325-335
162. Sanderson RD, Yang Y, Suva LJ, Kelly T (2004) Heparan sulfate proteoglycans and heparanase-partners in osteolytic tumor growth and metastasis. Matrix Biol 23:341-352 (Pubitemid 39469549)
163. Sanderson RD, Yang Y (2008) Syndecan-1: a dynamic regulator of the myeloma microenvironment. Clin Exp Metastasis 25:149-159
164. Oldberg A, Kalamajski S, Salnikov AV, Stuhr L, Mörgelin M, Reed RK, Heldin NE, Rubin K (2007) Collagen-binding proteoglycan fibromodulin can determine stroma matrix structure and fluid balance in experimental carcinoma. Proc Natl Acad Sci USA 104:13966-13971 (Pubitemid 350003321)
165. Colin C, Baeza N, Bartoli C, Fina F, Eudes N, Nanni I, Martin PM, Ouafik L, Figarella-Branger D (2006) Identification of genes differentially expressed in glioblastoma versus pilocytic astrocytoma using suppression subtractive hybridization. Oncogene 25:2818-2826
166. Kleeff J, Ishiwata T, Kumbasar A, Friess H, Büchler MW, Lander AD, Korc M (1998) The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer. J Clin Invest 102:1662-1673 (Pubitemid 28516251)
167. Matsuda K, Maruyama H, Guo F, Kleeff J, Itakura J, Matsumoto Y, Lander AD, Korc M (2001) Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells. Cancer Res 61:5562-5569 (Pubitemid 32694943)
168. Mundhenke C, Meyer K, Drew S, Friedl A (2002) Heparan sulfate proteoglycans as regulators of fibroblast growth factor-2 receptor binding in breast carcinomas. Am J Pathol 160:185-194 (Pubitemid 34052279)
169. Capurro MI, Xiang YY, Lobe C, Filmus J (2005) Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res 65:6245-6254 (Pubitemid 40994410)
170. Lambaerts K, Wilcox-Adelman SA, Zimmermann P (2009) The signaling mechanisms of syndecan heparan sulfate proteoglycans. Curr Opin Cell Biol 21:662-669
171. Xian X, Gopal S, Couchman JR (2010) Syndecans as receptors and organizers of the extracellular matrix. Cell Tissue 339:31-46
172. Cattaruzza L, Fregona D, Mongiat M, Ronconi L, Fassina A, Colombatti A, Aldinucci D (2011) Antitumor activity of gold(III)-dithiocarbamato derivatives on prostate cancer cells and xenografts. Int J Cancer 128:206-215
173. Grako KA, Stallcup WB (1995) Participation of the NG2 proteoglycan in rat aortic smooth muscle cell responses to plateletderived growth factor. Exp Cell Res 221:231-240
174. Liang Y, Häring M, Roughley PJ, Margolis RK, Margolis RU (1997) Glypican and biglycan in the nuclei of neurons and glioma cells: presence of functional nuclear localization signals and dynamic changes in glypican during the cell cycle. J Cell Biol 139:851-864 (Pubitemid 27508556)
175. Brockstedt U, Dobra K, Nurminen M, Hjerpe A (2002) Immunoreactivity to cell surface syndecans in cytoplasm and nucleus: tubulin-dependent rearrangements. Exp Cell Res 274:235-245 (Pubitemid 34946965)
176. Hsia E, Richardson TP, Nugent MA (2003) Nuclear localization of basic fibroblast growth factor is mediated heparan sulfate proteoglycans through protein kinase C signaling. J Cell Biochem 88:1214-1225 (Pubitemid 36397459)
177. Zong F, Fthenou E, Wolmer N, Hollósi P, Kovalszky I, Szilák L, Mogler C, Nilsonne G, Tzanakakis G, Dobra K (2009) Syndecan-1 and FGF-2, but not FGF receptor-1, share a common transport route and co-localize with heparanase in the nuclei of mesenchymal tumor cells. PLoS One 4:e7346
178. Chen L, Sanderson RD (2009) Heparanase regulates levels of syndecan-1 in the nucleus. PLoS One 4:e4947
179. De Luca A, Santra M, Baldi A, Giordano A, Iozzo RV (1996) Decorin-induced growth suppression is associated with up-regulation of p21, an inhibitor of cyclin-dependent kinases. J Biol Chem 271:18961-18965 (Pubitemid 26322772)
180. Moscatello DK, Santra M, Mann DM, McQuillan DJ, Wong AJ, Iozzo RV (1998) Decorin suppresses tumor cell growth by activating the epidermal growth factor receptor. J Clin Invest 101:406-412 (Pubitemid 28067338)
181. Csordás G, Santra M, Reed CC, Eichstetter I, McQuillan DJ, Gross D, Nugent MA, Hajnóczky G, Iozzo RV (2000) Sustained down-regulation of the epidermal growth factor receptor by decorin. A mechanism for controlling tumor growth in vivo. J Biol Chem 275:32879-32887
182. Goldoni S, Iozzo RV (2008) Tumor microenvironment: modulation by decorin and related molecules harboring leucine-rich tandem motifs. Int J Cancer 123:2473-2479
183. Zhu JX, Goldoni S, Bix G, Owens RT, McQuillan DJ, Reed CC, Iozzo RV (2005) Decorin evokes protracted internalization and degradation of the epidermal growth factor receptor via caveolar endocytosis. J Biol Chem 280:32468-32479 (Pubitemid 41361859)
184. Zafiropoulos A, Nikitovic D, Katonis P, Tsatsakis A, Karamanos NK, Tzanakakis GN (2008) Decorin-induced growth inhibition is overcome through protracted expression and activation of epidermal growth factor receptors in osteosarcoma cells. Mol Cancer Res 6:785-794
185. Goldoni S, Humphries A, Nyström A, Sattar S, Owens RT, McQuillan DJ, Ireton K, Iozzo RV (2009) Decorin is a novel antagonistic ligand of the Met receptor. J Cell Biol 185:743-745
186. Capurro MI, Xu P, Shi W, Li F, Jia A, Filmus J (2008) Glypican-3 inhibits Hedgehog signaling during development by competing with patched for Hedgehog binding. Dev Cell 14:700-711 (Pubitemid 351622615)
187. Mayr C, Bund D, Schlee M, Moosmann A, Kofler DM, Hallek M, Wendtner CM (2005) Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8? autologous T lymphocytes. Blood 105:1566-1573 (Pubitemid 40223676)
188. Choudhury A, Derkow K, Daneshmanesh AH, Mikaelsson E, Kiaii S, Kokhaei P, Osterborg A, Mellstedt H (2010) Silencing of ROR1 and FMOD with siRNA results in apoptosis of CLL cells. Br J Haematol 151:327-335
189. Morgan MR, Humphries MJ, Bass MD (2007) Synergistic control of cell adhesion by integrins and syndecans. Nat Rev Mol Cell Biol 8:957-969 (Pubitemid 350174639)
190. Stallcup WB, Dahlin K, Healy P (1990) Interaction of the NG2 chondroitin sulfate proteoglycan with type VI collagen. J Cell Biol 111:3177-3188 (Pubitemid 120034052)
191. Nishiyama A, Stallcup WB (1993) Expression of NG2 proteoglycan causes retention of type VI collagen on the cell surface. Mol Biol Cell 4:1097-1108 (Pubitemid 24007573)
192. Burg MA, Tillet E, Timpl R, Stallcup WB (1996) Binding of the NG2 proteoglycan to type VI collagen and other extracellular matrix molecules. J Biol Chem 271:26110-26116 (Pubitemid 26347453)
193. Tillet E, Gential B, Garrone R, Stallcup WB (2002) NG2 proteoglycan mediates beta1 integrin-independent cell adhesion and spreading on collagen VI. J Cell Biochem 86:726-736 (Pubitemid 34839974)
194. Sanderson RD, Sneed TB, Young LA, Sullivan GL, Lander AD (1992) Adhesion of B lymphoid (MPC-11) cells to type I collagen is mediated by integral membrane proteoglycan, syndecan. J Immunol 148:3902-3911
195. Ridley RC, Xiao H, Hata H, Woodliff J, Epstein J, Sanderson RD (1993) Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen. Blood 81:767-774 (Pubitemid 23040870)
196. Langford JK, Yang Y, Kieber-Emmons T, Sanderson RD (2005) Identification of an invasion regulatory domain within the core protein of syndecan-1. J Biol Chem 280:3467-3473 (Pubitemid 40223811)
197. Kibler C, Schermutzki F, Waller HD, Timpl R, Mü ller CA, Klein G (1998) Adhesive interactions of human multiple myeloma cell lines with different extracellular matrix molecules. Cell Adhes Commun 5:307-323 (Pubitemid 29141887)
198. Burg MA, Grako KA, Stallcup WB (1998) Expression of the NG2 proteoglycan enhances the growth and metastatic properties of melanoma cells. J Cell Physiol 177:299-312 (Pubitemid 28452831)
199. Yang Y, Yaccoby S, Liu W, Langford JK, Pumphrey CY, Theus A, Epstein J, Sanderson RD (2002) Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood 100:610-617 (Pubitemid 34761126)
200. Aikawa T, Whipple CA, Lopez ME, Gunn J, Young A, Lander AD, Korc M (2008) Glypican-1 modulates the angiogenic and metastatic potential of human and mouse cancer cells. J Clin Invest 118:89-99
201. Peters MG, Farías E, Colombo L, Filmus J, Puricelli L, Bal de Kier Joffé E (2003) Inhibition of invasion and metastasis by glypican-3 in a syngeneic breast cancer model. Breast Cancer Res Treat 80:221-232 (Pubitemid 36886511)
202. Stigliano I, Puricelli L, Filmus J, Sogayar MC, Bal de Kier Joffé E, Peters MG (2009) Glypican-3 regulates migration, adhesion and actin cytoskeleton organization in mammary tumor cells through Wnt signaling modulation. Breast Cancer Res Treat 114:251-262
203. Sanderson RD, Turnbull JE, Gallagher JT, Lander AD (1994) Fine structure of heparan sulfate regulates syndecan-1 function and cell behavior. J Biol Chem 269:13100-13106 (Pubitemid 24206070)
204. Kato M, Wang H, Bernfield M, Gallagher JT, Turnbull JE (1994) Cell surface syndecan-1 on distinct cell types differs in fine structure and ligand binding of its heparan sulfate chains. J Biol Chem 269:18881-18890 (Pubitemid 24226202)
205. Lebakken CS, McQuade KJ, Rapraeger AC (2000) Syndecan-1 signals independently of beta1 integrins during Raji cell spreading. Exp Cell Res 259:315-325
206. Hoffman MP, Nomizu M, Roque E, Lee S, Jung DW, Yamada Y, Kleinman HK (1998) Laminin-1 and laminin-2 G-domain synthetic peptides bind syndecan-1 and are involved in acinar formation of a human submandibular gland cell line. J Biol Chem 273:28633-286341
207. Yokoyama F, Suzuki N, Kadoya Y, Utani A, Nakatsuka H, Nishi N, Haruki M, Kleinman HK, Nomizu M (2005) Bifunctional peptides derived from homologous loop regions in the laminin alpha chain LG4 modules interact with both alpha 2 beta 1 integrin and syndecan-2. Biochemistry 44:9581-9589 (Pubitemid 40994352)
208. Hozumi K, Suzuki N, Nielsen PK, Nomizu M, Yamada Y (2006) Laminin alpha1 chain LG4 module promotes cell attachment through syndecans and cell spreading through integrin alpha2beta1. J Biol Chem 281:32929-32940 (Pubitemid 46036848)
209. Bachy S, Letourneur F, Rousselle P (2008) Syndecan-1 interaction with the LG4/5 domain in laminin-332 is essential for keratinocyte migration. J Cell Physiol 214:238-249 (Pubitemid 350220078)
210. Adams JC, Kureishy N, Taylor AL (2001) A role for syndecan-1 in coupling fascin spike formation by thrombospondin-1. J Cell Biol 152:1169-1182 (Pubitemid 34280175)
211. Beauvais DM, Rapraeger AC (2003) Syndecan-1-mediated cell spreading requires signaling by alphavbeta3 integrins in human breast carcinoma cells. Exp Cell Res 286:219-232 (Pubitemid 36566435)
212. Beauvais DM, Ell BJ, McWhorter AR, Rapraeger AC (2009) Syndecan-1 regulates alphavbeta3 and alphavbeta5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor. J Exp Med 206:691-705
213. Wang X, Osada T, Wang Y, Yu L, Sakakura K, Katayama A, McCarthy JB, Brufsky A, Chivukula M, Khoury T, Hsu DS, Barry WT, Lyerly HK, Clay TM, Ferrone S (2010) CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer. J Natl Cancer Inst 102:1496-1512
214. Park H, Kim Y, Lim Y, Han I, Oh ES (2002) Syndecan-2 mediates adhesion and proliferation of colon carcinoma cells. J Biol Chem 277:29730-29736
215. Choi S, Kim Y, Park H, Han IO, Chung E, Lee SY, Kim YB, Lee JW, Oh ES, Yi JY (2009) Syndecan-2 overexpression regulates adhesion and migration through cooperation with integrin alpha2. Biochem Biophys Res Commun 384:231-235
216. Choi Y, Kim H, Chung H, Hwang JS, Shin JA, Han IO, Oh ES (2010) Syndecan-2 regulates cell migration in colon cancer cells through Tiam1-mediated Rac activation. Biochem Biophys Res Commun 391:921-925
217. Vuoriluoto K, Jokinen J, Kallio K, Salmivirta M, Heino J, Ivaska J (2008) Syndecan-1 supports integrin alpha2beta1-mediated adhesion to collagen. Exp Cell Res 314:3369-3381
218. Vuoriluoto K, Högnäs G, Meller P, Lehti K, Ivaska J (2011) Syndecan-1 and-4 differentially regulate oncogenic K-ras dependent cell invasion into collagen through a2b1 integrin and MT1-MMP. Matrix Biol 30:207-217
219. Ishikawa T, Kramer RH (2010) Sdc1 negatively modulates carcinoma cell motility and invasion. Exp Cell Res 316:951-965
220. Børset M, Hjertner O, Yaccoby S, Epstein J, Sanderson RD (2000) Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins. Blood 96:2528-2536
221. Liebersbach BF, Sanderson RD (1994) Expression of syndecan-1 inhibits cell invasion into type I collagen. J Biol Chem 269:20013-20019 (Pubitemid 24250921)
222. Liu W, Litwack ED, Stanley MJ, Langford JK, Lander AD, Sanderson RD (1998) Heparan sulfate proteoglycans as adhesive and anti-invasive molecules. Syndecans and glypican have distinct functions. J Biol Chem 273:22825-22832 (Pubitemid 28399858)
223. Wilcox-Adelman SA, Denhez F, Goetinck PF (2002) Syndecan-4 modulates focal adhesion kinase phosphorylation. J Biol Chem 277:32970-32977 (Pubitemid 34984811)
224. Munesue S, Kusano Y, Oguri K, Itano N, Yoshitomi Y, Nakanishi H, Yamashina I, Okayama M (2002) The role of syndecan-2 in regulation of actin-cytoskeletal organization of Lewis lung carcinoma-derived metastatic clones. Biochem J 363:201-209 (Pubitemid 34415756)
225. Whiteford JR, Behrends V, Kirby H, Kusche-Gullberg M, Muramatsu T, Couchman JR (2007) Syndecans promote integrinmediated adhesion of mesenchymal cells in two distinct pathways. Exp Cell Res 313:3902-3913 (Pubitemid 47569976)
226. Bass MD, Morgan MR, Roach KA, Settleman J, Goryachev AB, Humphries MJ (2008) p190RhoGAP is the convergence point of adhesion signals from alpha 5 beta 1 integrin and syndecan-4. J Cell Biol 181:1013-1026 (Pubitemid 351846833)
227. Ridgway LD, Wetzel MD, Marchetti D (2010) Modulation of GEF-H1 induced signaling by heparanase in brain metastatic melanoma cells. J Cell Biochem 111:1299-1309
228. Fukushi J, Makagiansar IT, Stallcup WB (2004) NG2 proteoglycan promotes endothelial cell motility and angiogenesis via engagement of galectin-3 and alpha3beta1 integrin. Mol Biol Cell 15:3580-3590 (Pubitemid 38989698)
229. Iida J, Skubitz AP, Furcht LT, Wayner EA, McCarthy JB (1992) Coordinate role for cell surface chondroitin sulfate proteoglycan and alpha 4 beta 1 integrin in mediating melanoma cell adhesion to fibronectin. J Cell Biol 118:431-444
230. Iida J, Meijne AM, Spiro RC, Roos E, Furcht LT, McCarthy JB (1995) Spreading and focal contact formation of human melanoma cells in response to the stimulation of both melanomaassociated proteoglycan (NG2) and alpha 4 beta 1 integrin. Cancer Res 55:2177-2185
231. Yang J, Price MA, Neudauer CL, Wilson C, Ferrone S, Xia H, Iida J, Simpson MA, McCarthy JB (2004) Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanisms. J Cell Biol 165:881-891 (Pubitemid 38821978)
232. Makagiansar IT, Williams S, Dahlin-Huppe K, Fukushi J, Mustelin T, Stallcup WB (2004) Phosphorylation of NG2 proteoglycan by protein kinase C-alpha regulates polarized membrane distribution and cell motility. J Biol Chem 279:55262-55270 (Pubitemid 40066523)
233. Makagiansar IT, Williams S, Mustelin T, Stallcup WB (2007) Differential phosphorylation of NG2 proteoglycan by ERK and PKCalpha helps balance cell proliferation and migration. J Cell Biol 178:155-165 (Pubitemid 47026410)
234. Eisenmann KM, McCarthy JB, Simpson MA, Keely PJ, Guan JL, Tachibana K, Lim L, Manser E, Furcht LT, Iida J (1999) Melanoma chondroitin sulphate proteoglycan regulates cell spreading through Cdc42, Ack-1 and p130cas. Nat Cell Biol 1:507-513 (Pubitemid 129503671)
235. Majumdar M, Vuori K, Stallcup WB (2003) Engagement of the NG2 proteoglycan triggers cell spreading via rac and p130cas. Cell Signal 15:79-84 (Pubitemid 35223631)
236. Zeltz C, Brézillon S, Käpylä J, Eble JA, Bobichon H, Terryn C, Perreau C, Franz CM, Heino J, Maquart FX, Wegrowski Y (2010) Lumican inhibits cell migration through a2b1 integrin. Exp Cell Res 316:2922-2923
237. Iida J, Pei D, Kang T, Simpson MA, Herlyn M, Furcht LT, McCarthy JB (2001) Melanoma chondroitin sulfate proteoglycan regulates matrix metalloproteinase-dependent human melanoma invasion into type I collagen. J Biol Chem 276:18786-18794
238. Ryu HY, Lee J, Yang S, Park H, Choi S, Jung KC, Lee ST, Seong JK, Han IO, Oh ES (2009) Syndecan-2 functions as a docking receptor for pro-matrix metalloproteinase-7 in human colon cancer cells. J Biol Chem 284:35692-35701
239. Munesue S, Yoshitomi Y, Kusano Y, Koyama Y, Nishiyama A, Nakanishi H, Miyazaki K, Ishimaru T, Miyaura S, Okayama M, Oguri K (2007) A novel function of syndecan-2, suppression of matrix metalloproteinase-2 activation, which causes suppression of metastasis. J Biol Chem 282:28164-28174 (Pubitemid 47529519)
240. Buraggi GL, Callegaro L, Marlani G (1985) Imaging with 131llabeled monoclonal antibodies to a high-molecular-weight melanoma-associated antigen in patients with melanoma: efficacy of whole immunoglobulin and its F(ab0)2 fragments. Cancer Res 45:3378-3387 (Pubitemid 15007221)
241. Matzku S, Kirchgessner H, Schmid U, Temponi M, Ferrone S (1989) Melanoma targeting with a cocktail of monoclonal antibodies to distinct determinants of the human HMW-MAA. J Nucl Med 30:390-397 (Pubitemid 19077330)
242. Schrappe M, Bumol TF, Apelgren LD, Briggs SL, Koppel GA, Markowitz DD, Mueller BM, Reisfeld RA (1992) Long-term growth suppression of human glioma xenografts by chemoimmunoconjugates of 4-desacetylvinblastine-3-carboxyhydrazide and monoclonal antibody 9.2.27. Cancer Res 52:3838-3844
243. Wang B, Chen YB, Ayalon O, Bender J, Garen A (1999) Human single-chain Fv immunoconjugates targeted to a melanomaassociated chondroitin sulfate proteoglycan mediate specific lysis of human melanoma cells by natural killer cells and complement. Proc Natl Acad Sci USA 96:1627-1632 (Pubitemid 29098502)
244. Tordsson JM, Ohlsson LG, Abrahmsén LB, Karlström PJ, Lando PA, Brodin TN (2000) Phage-selected primate antibodies fused to superantigens for immunotherapy of malignant melanoma. Cancer Immunol Immunother 48:691-702 (Pubitemid 30146464)
245. Hafner C, Breiteneder H, Ferrone S, Thallinger C, Wagner S, Schmidt WM, Jasinska J, Kundi M, Wolff K, Zielinski CC, Scheiner O, Wiedermann U, Pehamberger H (2005) Suppression of human melanoma tumor growth in SCID mice by a human high molecular weight-melanoma-associated antigen (HMWMAA) specific monoclonal antibody. Int J Cancer 114:426-432 (Pubitemid 40279964)
246. Li Y, Wang J, Rizvi SM, Jager MJ, Conway RM, Billson FA, Allen BJ, Madigan MC (2005) In vitro targeting of NG2 antigen by 213Bi-9.2.27 alpha-immunoconjugate induces cytotoxicity in human uveal melanoma cells. Invest Ophthalmol Vis Sci 46:4365-4371 (Pubitemid 44264527)
247. Drake AS, Brady MT, Wang XH, Sait SJ, Earp JC, Ghoshal Gupta S, Ferrone S, Wang ES, Wetzler M (2009) Targeting 11q23 positive acute leukemia cells with high molecular weightmelanoma-associated antigen-specific monoclonal antibodies. Cancer Immunol Immunother 58:415-427
248. Saleh MN, Lalisan DY Jr, Pride MW, Solinger A, Mayo MS, LoBuglio AF, Murray JL (1998) Immunologic response to the dual murine anti-Id vaccine melimmune-1 and melimmune-2 in patients with high-risk melanoma without evidence of systemic disease. J Immunother 21:379-388 (Pubitemid 28452092)
249. Chang CC, Campoli M, Luo W, Zhao W, Zaenker K, Ferrone S (2004) Immunotherapy of melanoma targeting human high molecular weight melanoma-associated antigen. Ann N Y Acad Sci 1028:340-350
250. Peng L, Ko E, Luo W, Wang X, Shrikant PA, Ferrone S (2006) CD4-dependent potentiation of a high molecular weight-melanoma-associated antigen-specific CTL response elicited in HLA-A2/Kb transgenic mice. J Immunol 176:2307-2315 (Pubitemid 43201678)
251. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, Matrisian LM (2009) The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15:5323-5337
252. Chen ZJ, Yang H, Kageshita T, Ferrone S (1991) Human highmolecular-weight melanoma-associated antigen mimicry by mouse antiidiotypic monoclonal antibody TK7-371. Cancer Res 51:4790-4797
253. Chen ZJ, Yang H, Ferrone S (1991) Human high molecular weight melanoma-associated antigen mimicry by mouse antiidiotypic monoclonal antibody MK2-23. Characterization of the immunogenicity in syngeneic hosts. J Immunol 147:1082-1090
254. Wagner S, Hafner C, Allwardt D, Jasinska J, Ferrone S, Zielinski CC, Scheiner O, Wiedermann U, Pehamberger H, Breiteneder H (2005) Vaccination with a human high molecular weight melanoma-associated antigen mimotope induces a humoral response inhibiting melanoma cell growth in vitro. J Immunol 174:976-982 (Pubitemid 40103565)
255. Wang X, Ko EC, Peng L, Gillies SD, Ferrone S (2005) Human high molecular weight melanoma-associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: enhancement of immunogenicity of anti-idiotypic monoclonal antibody MK2-23 by fusion with interleukin 2. Cancer Res 65:6976-6983 (Pubitemid 41060738)
256. Chang CC, Hernandez-Guzman FG, Luo W, Wang X, Ferrone S, Ghosh D (2005) Structural basis of antigen mimicry in a clinically relevant melanoma antigen system. J Biol Chem 280:41546-41552 (Pubitemid 41832216)
257. Luo W, Ko E, Hsu JC, Wang X, Ferrone S (2006) Targeting melanoma cells with human high molecular weight-melanomaassociated antigen-specific antibodies elicited by a peptide mimotope: functional effects. J Immunol 176:6046-6054
258. Burns WR, Zhao Y, Frankel TL (2010) A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas. Cancer Res 70:3027-3033
259. Maciag PC, Seavey MM, Pan ZK, Ferrone S, Paterson Y (2008) Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature. Cancer Res 68:8066-8075
260. Ozerdem U, Stallcup WB (2004) Pathological angiogenesis is reduced by targeting pericytes via the NG2 proteoglycan. Angiogenesis 7:269-276
261. Ozerdem U (2006) Targeting of pericytes diminishes neovascularization and lymphangiogenesis in prostate cancer. Prostate 66:294-304 (Pubitemid 43191229)
262. Virgintino D, Ozerdem U, Girolamo F, Roncali L, Stallcup WB, Perris R (2008) Reversal of cellular roles in angiogenesis: implications for anti-angiogenic therapy. J Vasc Res 45:129-131 (Pubitemid 351651298)
263. Murray JL, Gillogly M, Kawano K, Efferson CL, Lee JE, Ross M, Wang X, Ferrone S, Ioannides CG (2004) Fine specificity of high molecular weight-melanoma-associated antigen-specific cytotoxic T lymphocytes elicited by anti-idiotypic monoclonal antibodies in patients with melanoma. Cancer Res 64:5481-5488 (Pubitemid 39006572)
264. Mittelman A, Chen ZJ, Yang H, Wong GY, Ferrone S (1992) Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc Natl Acad Sci USA 89:466-470
265. Mittelman A, Chen GZ, Wong GY, Liu C, Hirai S, Ferrone S (1995) Human high molecular weight-melanoma-associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: modulation of the immunogenicity in patients with malignant melanoma. Clin Cancer Res 1:705-713
266. Ho M, Kim H (2011) Glypican-3: a new target for cancer immunotherapy. Eur J Cancer 47:333-338